Holen Sie sich die Stockscreener-App
8.97
1.21%
-0.11
Handel nachbörslich:
8.97
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% HigherHere's What Happened - MarketBeat
Insider Buy: What is Zevra Therapeutics Incs market positionJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
Volume Recap: Will Zevra Therapeutics Inc benefit from geopolitical trendsEarnings Risk Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
The Technical Signals Behind (ZVRA) That Institutions Follow - Stock Traders Daily
Published on: 2026-01-17 12:49:06 - baoquankhu1.vn
J.P. Morgan: Zevra Sees EU As Land Of Opportunity For Miplyffa - Citeline News & Insights
Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C - MSN
Is Zevra Therapeutics (ZVRA) Using J.P. Morgan Spotlight To Reframe Its Rare-Disease Investment Story? - simplywall.st
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Zevra Therapeutics Reports Strong Q3 Earnings and Strategic Growth - MSN
Zevra Therapeutics FY 2024 Earnings Preview - MSN
Can Zevra Therapeutics Inc. stock withstand economic slowdownJuly 2025 Sentiment & Verified Entry Point Signals - ulpravda.ru
How Zevra Therapeutics Inc. stock benefits from tech adoptionJuly 2025 Rallies & Expert Approved Trade Ideas - ulpravda.ru
Can Zevra Therapeutics Inc. stock double in next 5 yearsJuly 2025 Gainers & Reliable Volume Spike Alerts - Улправда
Can Zevra Therapeutics Inc. stock sustain revenue growthTrade Performance Summary & Stock Market Timing Techniques - ulpravda.ru
Is Zevra Therapeutics Inc. stock a top pick in earnings season2025 Risk Factors & Fast Gain Swing Alerts - Улправда
Will Zevra Therapeutics Inc. stock deliver strong dividend growthWeekly Gains Report & Verified Momentum Stock Ideas - ulpravda.ru
What Wall Street predicts for Zevra Therapeutics Inc. stock priceAnalyst Downgrade & Precise Entry and Exit Recommendations - Улправда
Is Zevra Therapeutics Inc. stock a buy before product launchesWeekly Gains Summary & Weekly Stock Performance Updates - Улправда
Aug EndMonth: How Zevra Therapeutics Inc. (1GDA) stock reacts to fiscal policies2025 Price Targets & Accurate Entry and Exit Point Alerts - ulpravda.ru
Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference - The Manila Times
Zevra Therapeutics to Present at J.P. Morgan 44th Annual Healthcare Conference on January 15, 2026 - Quiver Quantitative
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Precision Trading with Zevra Therapeutics Inc. (ZVRA) Risk Zones - Stock Traders Daily
Sell Signal: How Zevra Therapeutics Inc stock benefits from tech adoptionLayoff News & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Is Zevra Therapeutics (ZVRA) Using Expanded Access To Quietly Recast Its Rare-Disease Growth Story? - Sahm
TheStreet - thestreet.com
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market - Seeking Alpha
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics announces CFO transition - MSN
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics stock maintains Buy rating at H.C. Wainwright on expanded access deal - Investing.com Nigeria
ZVRA Boosts Distribution for Miplyffa with Uniphar Agreement - GuruFocus
Zevra Therapeutics executes distribution agreement to broaden access to Miplyffa for the treatment of Niemann-Pick disease type C (NPC) - marketscreener.com
Zevra Therapeutics Signs Expanded Miplyffa Distribution Deal With Uniphar - marketscreener.com
Zevra Therapeutics (ZVRA) Expands MIPLYFFA Access with Uniphar A - GuruFocus
Zevra Therapeutics Signs Expanded Access Agreement with Uniphar to Enhance Availability of MIPLYFFA® for Niemann-Pick Disease Type C Patients - Quiver Quantitative
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) - The Manila Times
New deal expands access to a vital Niemann-Pick C treatment beyond Europe - Stock Titan
How Zevra Therapeutics Inc. (ZVRA) Affects Rotational Strategy Timing - Stock Traders Daily
Can Zevra Therapeutics Stock Hold Up When Markets Turn? - Trefis
Profit Review: How institutional buying supports Zevra Therapeutics Inc. stockJuly 2025 Trends & Long-Term Growth Stock Strategies - Улправда
Analysts’ Top Healthcare Picks: Zevra Therapeutics (ZVRA), Novan (NOVN) - The Globe and Mail
Discipline and Rules-Based Execution in ZVRA Response - Stock Traders Daily
Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? - Yahoo Finance
Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback? - Yahoo Finance
Does Zevra Therapeutics Near $8 Reflect Its 92% DCF Upside Potential in 2025? - simplywall.st
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics (ZVRA) director files report showing no holdings - Stock Titan
Schroder Investment Management Group Acquires New Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
2.92%
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):